Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for €6.7m plus a €0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA “liquid biopsy” analysis, a high growth area, is planned for 2016. C
27 Nov 2015
Rights issue to fund market development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rights issue to fund market development
Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for €6.7m plus a €0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA “liquid biopsy” analysis, a high growth area, is planned for 2016. C